The CAR-T therapies market is characterized by a healthy pipeline of promising therapies



Given the success of approved CAR-T cell therapies, such as KYMRIAH®, YESCARTA®, TECARTUS® and BREYANZI®, this upcoming class of biologics are anticipated to carve out a significant share of the multi-billion dollar cancer immunotherapy market

Press Release

Amazon Music Disney Promo

Roots Analysis has announced the addition of “CAR-T Cell Therapy Market (3rd Edition) by Target Indications (NHL, Multiple Myeloma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Hepatocellular Carcinoma and Others), Target Antigens– Industry Trends and Global Forecasts, 2021-2030” report to its list of offerings.

To order this 795+ page report, which features 165+ figures and 270+ tables, please visit



Given their ability to selectively direct a cell mediated immune response against cancer cells and, thereby, offer prolonged periods of disease remission, several CAR-T cell therapies provide a promising therapeutic strategy for advanced stage cancers and are expected to achieve blockbuster status



Key Market Insights


Over 755 CAR-T cell therapies are currently approved / under development

Close to 40% of the aforementioned candidates are in preclinical and discovery stages, while more than 25% are being evaluated in clinical stages (phase I/II and above). Examples of late-stage clinical candidates include bb2121, CD123/CLL1 CAR-T CD19 CAR-T and LCAR-B38M CAR-T / JNJ-68284528.



China is leading the product development efforts related to CAR-T cell therapies, in terms of number of active trials and supporting hospitals

In the last 10 years, over half of the 410 clinical trials evaluating various types of CAR-T cell therapies, were registered in China. In addition, owning to a favorable clinical research environment, China is presently considered to be among the leading regions in the CAR-T cell therapy space, with close to 40 industry players and more than 100 non-industry players, including hospitals and universities, contributing to this field.   


Key Questions Answered

  • Who are the leading industry and non-industry players in this market?
  • What are the prevalent R&D trends in CAR-T cell therapies domain?
  • What are the key therapeutic areas for which CAR-T cell therapies are being / have been developed?
  • What are the challenges faced by stakeholders in this industry?
  • Which are the key geographies where extensive research on CAR-T cell therapies is being conducted?


For additional details, please visit mailto:or email [email protected]



About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]



Ben Johnson

+1 (415) 800 3415

+44 (122) 391 1091

[email protected]